Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 216-230.W. Zwart, V. Theodorou, and J. S. Carroll, "Estrogen receptor- positive breast cancer: a multidisciplinary challenge," Wiley Interdisciplinary Reviews. Systems Biology and ...
Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med 2011;3:216-30.Zwart W, Theodorou V, Carroll JS. Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley interdisciplinary reviews Systems biology and medicine. 2011; 3 (2...
Estrogen receptor positive breast cancers and their association with environmental factorsdoi:10.1186/1476-072X-10-32Background Epidemiological studies to assess risk factors for breast cancer often do not differentiate between different types of breast cancers. We applied a general linear model to...
itself an ER target gene, is debated. We assess the issue in clinically relevant settings by a genetic approach and inject ER + breast cancer cell lines and patient-derived tumor cells
estrogen receptor modulator related hormone therapy (p=0.025) and aromatase inhibitors related hormone therapy (p=0.048). Moreover, LINC00309 was an independent predictor of worse disease-free survival in hormone-receptor positive breast cancer patients on univariate (HR=4.505; 95% CI 1.722-11.785;...
6. Jerusalem G, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer. JAMA Oncol. 2018;4(10):1367–1374. 7. Bray F, et al. Globa...
While CDK4/6 inhibitors (CDK4/6i) have improved outcomes for breast cancer patients, estrogen receptor (ER + ) breast cancers often develop resistance, and triple negative breast cancer (TNBC) show poor sensitivity. Here, the authors identify a vulnerability of CDK4/6i treated ER+ and ...
Estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative (ER+PR-HER2-) breast cancer comprise a special type of breast cancer that constitutes ~10% of all breast cancer patients. ER+PR-HER2- tumor benefits less from endocrine therapy...
Meaning The combination of clinical and molecular information may enhance the prognostic value for distant recurrence and risk stratification in estrogen receptor–positive, ERBB2-negative breast cancer, particularly for women with node-positive disease. Abstract Importance Multiple molecular signatures are av...
What Are the Potential Benefits and Harms of Taking Medications to Reduce Breast Cancer Risk? There is convincing evidence that tamoxifen, raloxifene, and aromatase inhibitors provide at least moderate benefit in reducing risk of invasive estrogen receptor-positive breast cancer in higher-risk women. ...